USPTO issued Patent US12590066B2 on March 31, 2026, granting Korea Institute of Science and Technology exclusive rights to fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and their uses. The patent covers chemical compounds classified under multiple CPC codes including C07D 217/24, C07D 215/227, C07D 235/26, C07D 263/58, C07D 277/68, and C07D 471/04. The application was filed on June 18, 2021, and contains 20 claims.

For compliance purposes, this represents a routine patent grant with no immediate compliance obligations. Pharmaceutical manufacturers or researchers developing similar heterocyclic compounds should review this patent to assess potential freedom-to-operate concerns or licensing opportunities. Legal professionals should note the CPC classifications for prior art searches.